Chronic pain hypersensitivity depends on N-methyl-D-aspartate receptors (NMDARs). However, clinical use of NMDAR blockers is limited by side effects resulting from suppression of the physiological functions of these receptors. Here we report a means to suppress pain hypersensitivity without blocking NMDARs, but rather by inhibiting the binding of a key enhancer of NMDAR function, the protein tyrosine kinase Src. We show that a peptide consisting of amino acids 40-49 of Src fused to the protein transduction domain of the HIV Tat protein (Src40-49Tat) prevented pain behaviors induced by intraplantar formalin and reversed pain hypersensitivity produced by intraplantar injection of complete Freund's adjuvant or by peripheral nerve injury. Src40-49Tat had no effect on basal sensory thresholds, acute nociceptive responses or cardiovascular, respiratory, locomotor or cognitive functions. Thus, through targeting of Src-mediated enhancement of NMDARs, inflammatory and neuropathic pain are suppressed without the deleterious consequences of directly blocking NMDARs, an approach that may be of broad relevance to managing chronic pain.
Chronic pain is categorized as inflammatory or neuropathic, each involving neuroplastic changes leading to hypersensitivity in peripheral and central nociceptive systems 1, 2 . Multiple mechanisms including increased primary afferent excitability 3 , enhanced transmission in the dorsal horn 1 , changes in gene expression 4 , aberrant neuron-glia interactions 5, 6 and neuronal apoptosis 7 are implicated in hypersensitivity in chronic pain models. Abundant preclinical evidence indicates that NMDARs 8 are crucial to pain hypersensitivity [9] [10] [11] . However, pharmacological blockade of these receptors in humans is deleterious because the activity of NMDARs is essential for many key physiological functions, including breathing and locomotion 9, 12, 13 . A crucial signaling event for NMDAR-dependent neuroplasticity, including pain hypersensitivity 1, 14 , is upregulation of NMDAR currents by mechanisms including relieving Mg 2+ blockade and receptor phosphorylation 15, 16 . Thus, preferentially inhibiting mechanisms that upregulate NMDARs without affecting basal channel activity represents a strategy that may suppress pain hypersensitivity without impairing key physiological functions.
NMDARs are multiprotein complexes comprised of a core tetrameric assembly-two NR1 subunits and two NR2A-2D subunitswhich form the ion channel conductance pathway 8, 17 . Within the NMDAR complex, the nonreceptor tyrosine kinase Src is a crucial regulatory hub through which multiple intracellular signaling cascades converge to increase NMDAR activity 16 . Src is anchored within the NMDAR complex through an adaptor protein, which we have identified as NADH dehydrogenase subunit 2 (ND2) 18 . Blocking the interaction between the Src unique domain and ND2 releases Src from the NMDAR complex, separating the enzyme and substrate, thereby inhibiting Src-mediated upregulation of NMDAR activity 18 . Hence, disrupting the Src-ND2 interaction is a strategy to treat pain that not only avoids the undesirable effects of blocking NMDAR function but also avoids directly inhibiting the catalytic activity of Src, a widely expressed kinase 19 . Here, we tested the hypothesis that uncoupling Src from the NMDAR complex may suppress pain hypersensitivity (Fig. 1a) .
RESULTS

Constructing a Src-NMDAR uncoupling peptide for use in vivo
To develop a practical reagent to disrupt anchoring of Src in the NMDAR complex in vivo, we synthesized a series of overlapping 10-amino-acid peptides covering Src40-58, the region in the unique domain we had previously identified in vitro as crucial for the Src-ND2 interaction 18 . We found that a peptide consisting of amino acids 40-49 of Src, Src40-49, but not Src45-54 or Src49-58, bound to ND2.1, the interacting region of ND2 (Fig. 1b) . Moreover, Src40-49 disrupted the interaction between the Src unique domain and ND2.1 in vitro ( Supplementary Fig. 1a online) .
Intracellular administration of Src40-49 reduced the NMDAR component of the miniature excitatory postsynaptic currents (mEPSCs) 20 in cultured dorsal horn neurons (Fig. 1c) , neurons in which NMDARs are tonically upregulated by Src 14, 21, 22 . By contrast, administering a peptide with identical amino acid composition but with a scrambled sequence (sSrc40-49) had no effect on synaptic NMDAR currents. The a-amino-3-hydroxy-5-methyl-4-isoxazole-priprionic acid receptor (AMPAR) component of the mEPSCs was unaffected by either Src40-49 or sSrc40-49. Thus, in vitro, Src40-49 disrupts the Src-ND2 interaction and reduces the upregulation of synaptic NMDARs.
Because Src40-49 is predicted to be membrane impermeant, this peptide itself is unsuitable for use in vivo. Therefore, we synthesized Src40-49, as well as sSrc40-49, fused to the protein transduction domain of the HIV-1 Tat protein 23 , generating Src40-49Tat and sSrc40-49Tat, respectively. Src40-49Tat, but not sSrc40-49Tat, bound the ND2.1 fragment of ND2 in vitro (Fig. 1d) . As we had previously observed with Src40-58 (ref. 18 ), Src40-49Tat did not bind the ND2.2 or ND2.3 fragments of ND2 ( Supplementary Fig. 1b) . Therefore, adding the Tat protein transduction domain did not abrogate the binding to ND2, and Src40-49Tat retained specificity for the ND2.1 region.
Next, we found that Src40-49Tat, but not sSrc40-49Tat, disrupted the direct interaction between the Src unique domain and ND2.1 (Fig. 1e) . Furthermore, by immunoprecipitating either NMDAR complexes or Src from rat brain crude synaptosomes we found that incubating them in vitro with Src40-49Tat, but not sSrc40-49Tat, suppressed their association (Fig. 1f,g ). Src40-49Tat also suppressed the association of Src with ND2 ( Fig. 1g) but had no effect on the interaction between ND2 and NMDARs ( Supplementary Fig. 1c ), indicating that Src40-49Tat caused a loss of Src from the NMDAR complex by inhibiting the binding of this kinase to ND2. In contrast, Src40-49Tat did not affect the association of Fyn or postsynaptic density protein 95 with NMDARs ( Supplementary Fig. 1d,e) , showing that this peptide did not generally disrupt interactions between proteins in the NMDAR complex. Moreover, Src40-49Tat had no effect on Src catalytic activity at the concentration that disrupted the Src-ND2 interaction or at 10 times this concentration (Supplementary Fig. 1g ), indicating that Src40-49Tat is not a Src kinase inhibitor per se.
Administering Src40-49Tat intravenously (i.v.) had no effect on the amount of Src, ND2 or NMDARs in rat brain synaptosomes. However, coimmunoprecipitation of ND2 and of NMDARs with Src was reduced in synaptosomes from rats in which Src40-49Tat had been administered in vivo as compared with synaptosomes from control rats (Fig. 1h) . From these collective findings, we concluded that Src40-49Tat is suitable for in vivo studies on the role of the Src-ND2 interaction in pain hypersensitivity.
Src40-49Tat prevents formalin-induced pain behaviors
We first tested Src40-49Tat in an inflammatory pain model in which dilute formalin was injected into the rat hindpaw, causing a stereotypic two-phase pattern of behavioral responses 24, 25 : phase 1 is independent of NMDARs, whereas phase 2 is NMDAR-dependent 4, 26 . We found that pretreating with Src40-49Tat (i.v. 45 min before formalin), but not sSrc40-49Tat, saline vehicle or Tat-protein transduction domain alone, significantly reduced formalin-induced phase 2 flinching (Fig. 2a,b) and biting or licking behaviors ( Supplementary Fig. 2a  online) . In contrast, responses in phase 1 were indistinguishable among all groups tested (Fig. 2c) . Moreover, i.v. of Src40-49Tat had no effect on formalin-induced paw edema 27 (Fig. 2d) .
We then tested the effect of Src40-49Tat, at 100 times the lowest maximally effective dose, on basal sensory thresholds and locomotor function in naive rats, and found no alteration in thermal or mechanical thresholds or rota-rod performance ( Supplementary  Fig. 2b-d) . Src40-49Tat i.v. also had no effect on heart rate, respiratory rate or oxygen saturation (Supplementary Table 1 online) . Therefore, administering Src40-49Tat suppresses the second, but not the first, phase of formalin-induced behaviors without causing observable changes in peripheral inflammation, basal sensory thresholds, locomotor performance or cardiorespiratory functions.
To determine whether Src40-49Tat may act within the spinal cord to suppress formalin-induced behaviors, we administered the peptide intrathecally (i.t.) at the lumbar level. We found that administering Src40-49Tat i.t. 30 min before formalin had no effect on behaviors in phase 1, whereas the peptide significantly reduced phase 2 behaviors (Fig. 2e,f and Supplementary Fig. 2e ). As the dose of Src40-49Tat i.t. was 20 times less than the minimal dose that produced an effect by i.v. injection, we concluded that when Src40-49Tat was given i.t., the suppression of phase 2 behaviors was mediated within the spinal cord.
We examined the effect of Src40-49Tat on the interactions between Src, ND2 and NMDARs in rats treated with formalin. Intravenously administering Src40-49Tat, but not sSrc40-49Tat, disrupted the association between Src and ND2 and between Src and NMDARs in the spinal cord ( Fig. 3a) without changing the association between ND2 and NMDARs ( Supplementary Fig. 1f ). Furthermore, we found that injection of formalin produced an approximately 2.5-fold increase in the level of tyrosine phosphorylation of the NR2B subunit of the NMDAR in the lumbar dorsal horn ipsilateral to the formalin injection (Fig. 3b) . This increase was prevented by Src40-49Tat (i.t.) but not by sSrc40-49Tat (Fig. 3c) . Thus, pretreating with Src40-49Tat suppressed formalin-induced behaviors, disrupted the Src-ND2 interaction in the spinal cord and reduced the formalin-induced increase in tyrosine phosphorylation of NR2B within the spinal cord.
Src40-49Tat reverses CFA-induced pain behaviors
We next investigated the effect of Src40-49Tat on established inflammatory pain using thermal and mechanical hypersensitivity evoked by intraplantar injection of complete Freund's adjuvant 28 (CFA; Fig. 4 ).
Intravenous administration of Src40-49Tat, but not vehicle or sSrc40-49Tat, caused an increase in the CFA-sensitized paw-withdrawal latency ( Fig. 4a-c) , indicating that the peptide inhibited the established thermal hypersensitivity. The magnitude of reversal of hypersensitivity increased with dose in the range of 0-10 pmol g -1 and persisted up to 120 min at the maximum dose of Src40-49Tat. Src40-49Tat, but not sSrc40-49Tat, also reversed the increase in tyrosine phosphorylation of NR2B in the ipsilateral spinal dorsal horn that occurred 1 d after injection of CFA (Fig. 4b, right) . Thermal hypersensitivity induced by CFA was also suppressed by i.v. administration of 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), a broad-spectrum inhibitor of Src family kinases (SFKs) 16 , which had a maximum effect similar to that of Src40-49Tat ( Supplementary Fig. 3a ,b online). The effects of PP2 and Src40-49Tat were not additive, however ( Supplementary Fig. 3b ), implying that broadly inhibiting SFKs produced no further reversal of the CFA-induced thermal hypersensitivity than did Src40-49Tat alone.
Another consequence of intraplantar CFA is mechanical hypersensitivity. We found that mechanical hypersensitivity was suppressed for up to 2 h by Src40-49Tat i.v. (Fig. 4d) but was unaffected by sSrc40-49Tat. Thus, Src40-49Tat reversed the established thermal and mechanical pain hypersensitivity produced by the inflammatory stimulus CFA.
Src40-49Tat does not affect learning
We investigated the possible effect of Src40-49Tat on two forms of NMDAR-dependent learning and memory: contextual fear conditioning 29 and conditioned taste aversion 30, 31 . In both tasks, we administered Src40-49Tat before training and then examined memory 3 d later. For contextual fear conditioning, Src40-49Tat, given i.v. at doses equal to or up to 100 times those eliciting maximal suppression of formalininduced behaviors, produced no change in freezing behavior as compared with saline controls ( Supplementary Fig. 4a ,b online). For conditioned taste aversion, Src 40-49Tat was microinfused bilaterally into the insular cortex 30 min before training. Src40-49Tat had no effect on taste preference during the choice test ( Supplementary  Fig. 4d ). As a positive control for the injection site, subsequent lidocaine microinfusion into the same group of mice was able to attenuate taste preference ( Supplementary Fig. 4e ). Thus, in two behavioral paradigms, Src40-49Tat did not affect learning and memory. 
Suppression of inflammatory pain behaviors requires Src
We investigated the Src dependency of the effects of Src40-49Tat on inflammatory pain behaviors using Src -/-mice 32 . Src -/-mice were not different from wild-type littermate controls in acute thermal or mechanical nociceptive responses, in locomotor function as measured by the accelerated rota-rod test ( Supplementary Fig. 5a-d online) , in Morris water maze testing, or in contextual fear conditioning (Supplementary Fig. 5e,f) . Formalin-induced behaviors in phase 1 were unaltered in Src -/-mice (Fig. 5a) . However, formalin-induced behaviors in phase 2 were significantly reduced in Src -/-mice as compared with wild-type littermate controls (Fig. 5a,b) . There was no difference between wild-type and Src -/-mice in the basal degree of tyrosine phosphorylation of NR2B in dorsal spinal cord ( Supplementary Fig. 6a online) . However, after formalin administration, the increase in tyrosine phosphorylation of NR2B in the spinal dorsal horn in the wild-type mice did not occur in Src -/-mice (Fig. 5c) . Thus, as anticipated from our findings with administering Src40-49Tat, formalin-induced behaviors in the second phase, but not in the first phase, and formalin-induced NR2B tyrosine phosphorylation in the dorsal horn are dependent on Src.
We reasoned that if the effects of Src40-49Tat are mediated by uncoupling of Src from the NMDAR complex, then these effects will be lost in the absence of Src. To test this idea, we compared the effect of Src40-49Tat on formalin-induced behaviors in Src -/-mice versus wild-type littermates. As with our findings in rats, administering Src40-49Tat i.v. 45 min before formalin in wild-type mice had no effect on phase 1 behaviors (Fig. 5d) but significantly reduced formalin-induced phase 2 behaviors (Fig. 5d,e) . By contrast, in the Src -/-mice, i.v. administered Src40-49Tat had no effect on formalininduced phase 2 behaviors ( Fig. 5f and Supplementary Fig. 6b,c) . Because phase 2 behaviors were suppressed in Src -/-mice but were not further inhibited by Src40-49Tat, we infer that the effect of the peptide was occluded in the Src -/-mice. Formalin-induced behaviors in Src -/-mice were suppressed by morphine ( Supplementary Fig. 7a online) , indicating that these mice are not generally resistant to analgesics. Thus, our results indicate that the suppression of inflammatory pain behaviors by Src40-49Tat is Src dependent.
Src40-49Tat reverses nerve-induced pain behaviors
We next tested Src40-49Tat on neuropathic pain behaviors using a model of peripheral nerve injury (PNI) in rats, characterized by a reduction of mechanical paw withdrawal threshold and cold-induced sensitization 33, 34 . The effect of Src40-49Tat on mechanical withdrawal threshold was assessed 8-15 d after PNI 5, 35 . We found that Src40-49Tat, but not sSrc40-49Tat or saline vehicle, caused a significant increase in paw withdrawal threshold ipsilateral to the nerve injury when administered either i.t. (Fig. 6a) or i.v. (Fig. 6b) . The increase in paw withdrawal threshold developed within the first hour, and, with i.t. administration, the effect persisted for the 5-h testing period (Fig. 6a) . With i.v. administration, the increase in paw withdrawal threshold peaked approximately 2 h after injecting Src40-49Tat (Fig. 6b) . With either i.t. or i.v. administration, the paw withdrawal threshold had returned to the preinjection level by 24 h after the peptide was injected (data not shown). Cold-induced sensitization was assessed by applying a drop of acetone to the plantar surface of the paw, which evokes flinching and licking or biting behaviors of the hind paw ipsilateral to PNI 36 . Administering Src40-49Tat significantly reduced acetone-induced behaviors but sSrc40-49Tat had no effect ( Fig. 6c and Supplementary  Fig. 7b) .
We found that the amount of tyrosine phosphorylation of NR2B in the ipsilateral spinal cord was significantly increased by PNI, with no effect on total NR2B (Fig. 6d) . Intrathecal administration of Src40-49Tat reduced the level of NR2B tyrosine phosphorylation in PNI rats to a level not different from that in sham controls (Fig. 6d) . Collectively, our results indicate that Src40-49Tat reverses PNIinduced mechanical and cold sensitization and that, acting at the level of the spinal cord, Src40-49Tat normalizes PNI-induced NR2B tyrosine phosphorylation.
We tested the Src dependency of PNI-induced mechanical hypersensitivity by comparing Src -/-mice and wild-type littermate controls. In wild-type mice, PNI caused a marked reduction in paw withdrawal threshold of the ipsilateral paw beginning 1 d after PNI and persisting for more than 3 weeks (Fig. 6e) . In Src -/-mice, the reduction in paw withdrawal threshold was significantly less than that in the wild-type mice throughout the 22-d period during which the mice were examined (Fig. 6e) . Correspondingly, the PNI-induced increase in tyrosine phosphorylation of NR2B in the ipsilateral dorsal spinal cord was reduced in Src -/-mice compared with that in wild-type littermates (Fig. 6e) . Src40-49Tat i.v. significantly increased paw withdrawal threshold in wild-type mice 14 d after PNI to a level not different from that in the Src -/-mice without peptide administration (Fig. 6f) . However, Src40-49Tat had no effect on paw withdrawal threshold in the Src -/-mice. Likewise, when administered 3 d after PNI, Src40-49Tat significantly (P ¼ 0.041) increased paw withdrawal threshold in wild-type mice but not in Src -/-mice ( Supplementary  Fig. 7c ). Thus, we concluded that the suppression of mechanical hypersensitivity by Src40-49 was occluded in Src -/-mice, and, as such, that this effect is Src-dependent.
DISCUSSION
Our findings show that the Src40-49Tat peptide, but not the scrambled Src40-49Tat peptide, suppressed pain hypersensitivity induced by inflammation and peripheral nerve injury. By contrast, Src40-49Tat caused no alteration in acute thermal, mechanical or chemical nociception. Because there seemed to be no confounding sedative, motor depressant or cognitive effects of the peptide (see Supplementary Discussion online), we conclude that Src40-49Tat suppresses pain hypersensitivity, and that behaviors in models of chronic pain are suppressed preferentially with respect to those in acute nociception. Moreover, in Src -/-mice, both the formalin-and PNI-induced pain hypersensitivities were reduced, and the effects of Src40-49Tat were occluded in these mice. Together, these findings show that a common link between inflammatory and neuropathic pain behaviors is dependence on Src. The most parsimonious interpretation of our findings is that the suppression of pain hypersensitivity behaviors by Src40-49Tat may be mediated by disruption of the Src-ND2 interaction and subsequent inhibition of Src-induced enhancement of NMDAR function.
We designed Src40-49Tat to inhibit the interaction of Src with its anchoring protein, ND2, in the NMDAR complex. The binding of Src40-49Tat to ND2 in and of itself cannot account for the behavioral effects of the peptide, because the ND2 level within the NMDAR complex is not changed in Src -/-mice 37 , and yet the pain hypersensitivity was not affected by Src40-49Tat in these mice. By similar reasoning, potential binding of Src40-49Tat to molecules other than ND2 may remain in Src -/-mice and, thus, such off-target interactions, if they exist, are not responsible for the suppression of pain hypersensitivity by the peptide. Rather, the suppression of pain hypersensitivity by Src40-49Tat may require an intact interaction between Src and ND2, which is inhibited by the peptide. It is conceivable that Src40-49Tat might inhibit an interaction of Src with a partner other than ND2, one that has the same Src40-49 binding motif as ND2. However, the Src-binding region of ND2, which is highly conserved in mice, rats and humans 18 , contains no known conserved domains or motifs, and shows minimal primary sequence homology to other proteins.
Within the NMDAR complex, Src enhances NMDAR function by increasing channel open time and open probability upon binding of the coagonists glutamate and glycine, leading to increased synaptic NMDAR currents 14 . Src is opposed by striatal enriched tyrosine phosphatase 21 , and the balance of the activity between these two enzymes provides dynamic gain control of NMDAR function 16 . Our findings indicate that peripheral inflammation causes a rapid onset and sustained Src-dependent increase in tyrosine phosphorylation, which may enhance the function of NMDARs in the spinal cord. The reversal of the decreased paw withdrawal threshold by Src40-49Tat several weeks after PNI likewise implies that there is an ongoing increase in Src activity relative to striatal enriched tyrosine phosphatase, which is required to sustain pain hypersensitivity after PNI. Many candidate intracellular signaling pathways might cause the relative increase in Src activity within the NMDAR complex 16, 38, 39 that produces pain hypersensitivity, and it is conceivable these pathways may be common, or distinct, for inflammatory versus neuropathic pain.
The kinase most closely related to Src is Fyn, and PNI-induced behaviors are suppressed in Fyn -/-mice 40 , indicating that Fyn may also be important for these behaviors. It is known that Fyn does not interact with ND2 (ref. 18) , and here we found that Src40-49Tat does not affect the association of Fyn with NMDARs. Moreover, the effects of Src40-49Tat were prevented in Src -/-mice, which do express Fyn. Collectively, these findings indicate that Src40-49Tat does not act directly through Fyn. In the case of PNI, it is possible that Fyn may be downstream of Src and, hence, that Fyn might be indirectly affected by Src40-49Tat.
Inhibitors of SFKs targeting the catalytic domain have been reported to reduce CFA-induced mechanical hyperalgesia 41 and PNI-induced behaviors 42 , and we show here that PP2 reduces CFA-induced thermal hyperalgesia. SFK inhibitors do not distinguish well between members of the Src family 43 . By contrast, Src40-49 corresponds to a sequence in the unique domain which has no primary sequence homology to that in any other SFK. Catalytic domain inhibitors block the kinase regardless of substrate. However, Src40-49Tat does not inhibit kinase catalytic activity but rather separates the kinase from its substrate. Thus, two strategic advantages of Src40-49Tat are that it suppresses the action of Src differentially from other SFKs, and that it does this only for substrates where Src targeting to the protein depends upon the Src-ND2 interaction, as does that of the NMDAR 18 .
Distinguishing between inflammatory versus neuropathic pain may be difficult clinically. Thus, an efficacious therapy that simultaneously suppresses both inflammatory and neuropathic pain, and at the same time has a wide therapeutic window, would have the advantage of being effective and safe and could simplify pain management strategies. Our present discoveries open up the possibility that such a therapeutic approach may be achieved by targeting the Src-mediated enhancement of NMDAR function. NMDARs are implicated in many disease processes in the central nervous system, including neurodegenerative disorders, epilepsy and stroke. From our present findings, it is possible that potentiated NMDAR function, by Src or other pathways, rather than basal receptor function, is crucial for these disorders as well. Thus, our findings reveal a strategy relevant to the treatment of chronic pain and potentially other NMDAR-dependent central nervous system pathologies.
METHODS
Animals. All animals were used in accordance with the guidelines of the Canadian Council on Animal Care. All protocols were approved by the Animal Care Committee of the Hospital for Sick Children. We purchased male Sprague-Dawley rats used for behavioral studies from Charles River. We introduced the c-Src null mutation by homologous recombination into embryonic stem cells as described previously 32 . The mice used in contextual fear and conditioned taste aversion experiments were the offspring (F 1 ) from a cross between C57BL/6Tac (B6; Taconic Farms) and 129Sv/Tac (129; Taconic Farms). We bred mice in the animal colony at the Hospital for Sick Children according to Research Institute guidelines.
Models for inflammatory or neuropathic pain. To produce inflammatory pain, we subcutaneously injected formalin (2.5%, 50 ml for rats; 1.5%, 20 ml for mice) or CFA (0.05 ml Mycobacterium tuberculosis) into the plantar hindpaw. For the formalin test, we observed two animals (rats or mice) in adjacent chambers at one time, for flinching behaviors or biting and licking time 44 with observations occurring in alternate 2-min periods out of a 4-min bin. Data are presented either as a time course, or the cumulative number of flinches and the total amount of time with biting and licking behaviors during phase 1 (0-8 min) or phase 2 (9-60 min). For the CFA model, we measured thermal paw withdrawal latency (PWL) 28, 45 and mechanical paw withdrawal threshold (PWT) in rats. Results are presented either as raw data or normalized for each rat as the percentage maximal possible effect (MPE) in terms of the change in the PWL ipsilateral to CFA. We calculated these values as follows: percentage MPE ¼ (time x PWL À time 0 PWL) / (baseline À time 0 PWL). Time 0 is the PWL 24 h after CFA, before drug administration. Time x is the time point following injection of Src40-49Tat, PP2 or their respective controls. To produce peripheral nerve injury (PNI), we surgically implanted a polyethylene cuff (2 mm in length) around the sciatic nerve of rats or mice under isoflurane anesthesia 5, 35 . We measured mechanical PWT 5, 35 and cold sensitization 36 as previously described. See Supplementary Methods online for details of thermal PWL testing, mechanical PWT testing and cold sensitization testing.
Peptides. Src40-49 (KPASADGHRG), scrambled Src40-49 (GAAKRPSDGH), Tat protein transduction domain (YGRKKRRQRRR), Src40-49Tat (KPA SADGHRGYGRKKRRQRRR) and scrambled Src40-49Tat (GAAKRPSDG HYGRKKRRQRRR) were synthesized by the Advanced Protein Technology Center.
Coimmunoprecipitation, immunoprecipitation and immunoblotting. For coimmunoprecipitation, we prepared NMDAR and its associated proteins from the crude synaptosomal fraction of forebrain or spinal cord as described previously 21 . For in vitro competition experiments, we incubated Src40-49Tat or Scrambled Src40-49Tat (10 mM) with the lysate 30 min before adding antibody for immunoprecipitation.
For immunoprecipitation to examine the relative tyrosine phosphorylation of NR2B, we rapidly removed the dorsal lumbar spinal cord ipsilateral to formalin or CFA or PNI. Each sample contained proteins from one rat or mouse, and we homogenized, immunoprecipitated and analyzed each sample individually. We homogenized spinal cord as described 41 in ice-cold RIPA buffer. We then centrifuged the samples and determined the protein concentration. Next we incubated samples with NR2B antiserum (Santa Cruz Biotechnology) overnight. We isolated immune complexes with protein G-Sepharose beads, resolved them using SDS-PAGE and transferred them to nitrocellulose membranes. We first probed membranes with an antibody against phosphotyrosine, then stripped and reprobed them with an antibody against NR2B. For densitometric quantification, we digitized and quantified immunoblots using ImageJ software. We obtained the relative phosphotyrosine NR2B band density (relative p-NR2B density) levels by normalizing the antiphosphotyrosine immunoblot against the corresponding NR2B subunit immunoblot from the same sample. A linear detection range was established for each antibody used, and only values falling in this linear range were incorporated into the final quantitative analysis.
Electrophysiological recordings. We made whole-cell recordings from cultured dorsal horn neurons as described 20 . We added Src40-49 or sSrc40-49 to the intracellular solution for a final concentration of 0.015 mg ml -1 . We recorded whole-cell currents with an AxoPatch 200B amplifier (Axon Instruments) and digitized (20 KHz) and analyzed them offline. We detected and analyzed mEPSCs offline (MiniAnalysis Program, Synaptosoft). Average mEPSCs observed in the first 2 min after breaking in whole-cell configuration were used as control and compared to averages obtained after 8-14 min in whole cell. The AMPA component was measured at the maximum amplitude during the first 5 ms in each event and the NMDA component as the integrated charge between 5 and 150 ms after the peak value 15 . Mean mEPSCs contained at least 30 traces. See Supplementary Methods online for more details.
Statistical analyses. We used analysis of variance or Student's t-test to determine significant differences between sample groups. P o 0.05 was considered significant in all cases.
Note: Supplementary information is available on the Nature Medicine website.
